Cardiol Therapeutics (NASDAQ:CRDL) Research Coverage Started at Roth Mkm

Roth Mkm began coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL) in a research report released on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 target price on the stock.

Several other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group increased their price objective on Cardiol Therapeutics from $6.00 to $8.00 and gave the stock a buy rating in a report on Thursday, May 23rd. HC Wainwright restated a buy rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Friday, June 14th. Finally, Canaccord Genuity Group raised their target price on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a buy rating in a research note on Thursday, May 23rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $7.60.

Cardiol Therapeutics Price Performance

Shares of Cardiol Therapeutics stock opened at $2.02 on Wednesday. The company has a current ratio of 2.81, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $139.38 million, a PE ratio of -5.77 and a beta of 0.99. The business’s 50-day moving average price is $2.21 and its 200-day moving average price is $1.65. Cardiol Therapeutics has a 12 month low of $0.66 and a 12 month high of $3.12.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). Sell-side analysts forecast that Cardiol Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Trading of Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Tejara Capital Ltd grew its holdings in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 29.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 645,457 shares of the company’s stock after purchasing an additional 148,396 shares during the period. Tejara Capital Ltd owned about 1.00% of Cardiol Therapeutics worth $578,000 as of its most recent SEC filing. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.